In the whole cohort, Predict Tool predicted 5-year OS accurately: 79.5% compared with observed survival of 79.9% (difference of –0.4%, 95% confidence interval [CI] –2.4 to 1.6). However, it did not perform well in women younger than 40years: 5-year OS was overestimated by 10.2% (...
1 The PREDICT online tool aims to help inform clinician and patient decisions about adjuvant therapy following breast cancer surgery. Provided with input of a patient’s clinical characteristics, PREDICT provides personalised prognostic information displayed as 5-year and 10-year overall survival ...
A team of researchers at the University of California, San Francisco has discovered a new way to predict breast cancer survival based on an "immune profile" – the relative levels of three types of immune cells within a tumor. Knowing a patient's profile may one day help guide treatment. M...
evaluating the prognostic role of PREDICT+ in the patients with HER2-positive early breast cancer. PREDICT+ is a widely used online tool that helps to show how the treatments administered after a breast cancer surgery can really improve the survival rate. ...
The CTC results are available about 4 weeks after start of therapy. Conventional imaging is carried out after about 3 months. But an expert is not convinced that this approach is currently ready for clinical use and suggests that for now, it should remain a tool for use in research. ...
The activity of two genes may help predict certain breastcancer patients’chances of survival and guide their treatment, British researchers report.“We have seen major strides in thetreatment of breast cancer, but once it begins to spread round the body it is still often fatal,” said Paul Wo...
Research introduced at SNM's 57th Annual Meeting is expanding molecular imaging's role in determining the best course of treatment for recurring breast cancer patients, while offering a means of evaluating certain therapies for potentially positive impact on their chance of survival. ...
Micrometastases predict relapse and survival in high-risk breast cancerdoi:10.1038/ncponc0618NoneNature Clinical Practice Oncology
An increased number of resources are allocated on cancer biomarker discovery, but very few of these biomarkers are clinically adopted. To bridge the gap between Biomarker discovery and clinical use, we aim to generate the Biomarker Toolkit, a tool designed to identify clinically promising biomarkers ...
Cancer centers do not all routinely collect data on RCB; this analysis indicates that RCB is a potential predictor of recurrence acrossbreastcancer subtypes. "These findings indicate the importance of implementing residual cancer burden screening as a standard tool during cancer treatment. Routinizing ...